newsfilter
← Earnings
Earnings Releases·

Artiva Biotherapeutics — Q3 2026 Earnings Summary

  • The Company reported approximately $319.1 million in cash, cash equivalents, and investments as of September 30, 2026, while implementing a 94% workforce reduction to preserve capital.
  • Development of lead candidate AlloNK® (AB-101) has been permanently halted following two Grade 5 safety events and a failure to meet durability thresholds, resulting in the cancellation of the planned Phase 3 trial.
  • The Board is evaluating strategic alternatives including a merger, sale, or liquidation with Leerink Partners engaged as financial advisor; no further updates will be provided until a specific course of action is approved.
  • The Company will not initiate additional dosing in ongoing studies, canceled upcoming data presentations, and intends to share details of the fludarabine-associated neurotoxicity case in a scientific publication.
Company
ARTIVA BIOTHERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology